LncRNAs: Emerging biomarkers and therapeutic targets in rectal cancer DOI

Abida Abida,

Mohd Imran, Lina Eltaib

и другие.

Pathology - Research and Practice, Год журнала: 2024, Номер 257, С. 155294 - 155294

Опубликована: Апрель 5, 2024

Язык: Английский

MALAT1: A key regulator in lung cancer pathogenesis and therapeutic targeting DOI
Asif Ahmad Bhat, Obaid Afzal, Muhammad Afzal

и другие.

Pathology - Research and Practice, Год журнала: 2023, Номер 253, С. 154991 - 154991

Опубликована: Ноя. 30, 2023

Язык: Английский

Процитировано

56

Janus kinase/signal transducers and activator of transcription (JAK/STAT) and its role in Lung inflammatory disease DOI
Manish Purohit, Gaurav Gupta, Obaid Afzal

и другие.

Chemico-Biological Interactions, Год журнала: 2023, Номер 371, С. 110334 - 110334

Опубликована: Янв. 5, 2023

Язык: Английский

Процитировано

30

From carcinogenesis to therapeutic avenues: lncRNAs and mTOR crosstalk in lung cancer DOI
Md Sadique Hussain, Abdulmalik Saleh Alfawaz Altamimi, Muhammad Afzal

и другие.

Pathology - Research and Practice, Год журнала: 2023, Номер 253, С. 155015 - 155015

Опубликована: Дек. 6, 2023

Язык: Английский

Процитировано

25

Exosomal ncRNAs in liquid biopsies for lung cancer DOI
Md Sadique Hussain, Gaurav Gupta, Nehmat Ghaboura

и другие.

Clinica Chimica Acta, Год журнала: 2024, Номер 565, С. 119983 - 119983

Опубликована: Окт. 3, 2024

Язык: Английский

Процитировано

15

Circular RNAs in the KRAS pathway: Emerging players in cancer progression DOI
Md Sadique Hussain, Ehssan Moglad, Muhammad Afzal

и другие.

Pathology - Research and Practice, Год журнала: 2024, Номер 256, С. 155259 - 155259

Опубликована: Март 11, 2024

Язык: Английский

Процитировано

12

PVT1 lncRNA in lung cancer: A key player in tumorigenesis and therapeutic opportunities DOI
Mohammed Ageeli Hakami, Ali Hazazi, Farhan R. Khan

и другие.

Pathology - Research and Practice, Год журнала: 2023, Номер 253, С. 155019 - 155019

Опубликована: Дек. 7, 2023

Язык: Английский

Процитировано

19

Safety and effectiveness of CIMAvax-EGF administered in community polyclinics DOI Creative Commons

Ramón A. Ortiz Carrodeguas,

Geidy Lorenzo Monteagudo,

Pedro P. Guerra Chaviano

и другие.

Frontiers in Oncology, Год журнала: 2024, Номер 13

Опубликована: Янв. 18, 2024

In spite of the advances in immunotherapy and targeted therapies, lung cancer continues to be leading cause cancer-related death. The epidermal growth factor receptor is an established target for non-small cell (NSCLC), its overactivation by ligands can induce accelerated proliferation, angiogenesis, metastasis as well proinflammatory or immunosuppressive signals. CIMAvax-EGF (EGF)-depleting that approved treatment NSCLC patients Cuba. study was designed a phase IV trial characterize safety effectiveness advanced treated 119 community polyclinics 24 hospitals. consisted four bi-weekly doses followed monthly boosters. Overall, 741 ineligible further cancer-specific were enrolled. safe, most common adverse events mild-to-moderate injection site reactions, fever, chills, tremors, headache. For completing loading doses, median survival 9.9 months. individuals achieving at least stable disease frontline vaccination induction, 12 Most functional activities symptoms evaluated through European Organisation Research Treatment Cancer (EORTC) QLQ-C30 questionnaire improved over time. conclusion, this real-world demonstrated safe effective who vaccinated maintenance scenario. A larger effect seen subjects with poor prognosis like those squamous tumors high EGF levels. Remarkably, community-based intervention very important because it feasibility treating active primary care institutions. addition CIMAvax-EGF, received supportive clinic. Vaccine administration family doctors reduced patients’ burden on medical oncology services continued providing chemotherapy other complex therapies. We conclude constitute optimal scenario administering vaccines are require prolonged cancer, despite continuous deterioration their general condition. Clinical registration https://rpcec.sld.cu/trials/RPCEC00000205-En , identifier RPCEC00000205.

Язык: Английский

Процитировано

7

Targeting notch-related lncRNAs in cancer: Insights into molecular regulation and therapeutic potential DOI

Raihan Siddique,

Gaurav Gupta,

Johar MGM

и другие.

Pathology - Research and Practice, Год журнала: 2024, Номер 257, С. 155282 - 155282

Опубликована: Апрель 1, 2024

Язык: Английский

Процитировано

7

Ferroptosis and circular RNAs: new horizons in cancer therapy. DOI
Asif Ahmad Bhat,

Neelima Kukreti,

Muhammad Afzal

и другие.

PubMed, Год журнала: 2024, Номер 23, С. 570 - 599

Опубликована: Янв. 1, 2024

Cancer poses intricate challenges to treatment due its complexity and diversity. Ferroptosis circular RNAs (circRNAs) are emerging as innovative therapeutic avenues amid the evolving landscape of cancer therapy. Extensive investigations into circRNAs reveal their diverse roles, ranging from molecular regulators pivotal influencers ferroptosis in cell lines. The results underscore significance modulating pathways that impact crucial aspects development, including survival, proliferation, metastasis. A detailed analysis delineates these pathways, shedding light on mechanisms through which influence ferroptosis. Building upon recent experimental findings, study evaluates potential targeting induce By identifying specific associated with etiology cancer, this paves way for development targeted therapeutics exploit vulnerabilities cells. This review consolidates existing understanding circRNAs, emphasizing role therapy providing impetus ongoing research dynamic field. See also graphical abstract(Fig. 1).

Язык: Английский

Процитировано

7

Design, synthesis, cytotoxic activities, and molecular docking of chalcone hybrids bearing 8-hydroxyquinoline moiety with dual tubulin/EGFR kinase inhibition DOI

Mohammed M. Amin,

Gamal El‐Din A. Abuo‐Rahma, Montaser Sh. A. Shaykoon

и другие.

Bioorganic Chemistry, Год журнала: 2023, Номер 134, С. 106444 - 106444

Опубликована: Фев. 25, 2023

Язык: Английский

Процитировано

15